Prolia (Denosumab) Adolescent (12 to 17) Developmental Impact
A clinical review of how denosumab (Prolia) affects bone development, growth plates, puberty, and long-term skeletal outcomes in adolescents aged 12 to 17.
Age V2 Denosumab
14 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
14articles
3topic areas covered
Jan 20, 2025latest review
Age V2 Denosumab library
Showing 14 of 14 clinical reviews.
Prolia (Denosumab) Adolescent (12 to 17) Transition to Adult Care
A clinician-reviewed guide to transitioning adolescents aged 12 to 17 from denosumab therapy to adult osteoporosis care, covering rebound risk, monitoring, and step-down protocols.
Prolia (Denosumab) Adolescent (12 to 17): School and Activity Considerations
A clinical guide for teens aged 12 to 17 on denosumab (Prolia): how to manage school attendance, gym class, sports, and daily activities safely during treatment.
Prolia (Denosumab) Adolescent (12-17) Caregiver Administration Guidance
A complete caregiver guide to administering Prolia (denosumab) subcutaneous injections to adolescents aged 12-17, including step-by-step technique, storage, missed-dose protocols, and safety monitoring backed by FDA labeling and clinical evidence.
Prolia (Denosumab) Geriatric (65+) Caregiver Administration Guidance
A complete caregiver guide to administering Prolia (denosumab) 60 mg subcutaneous injection in adults aged 65 and older, covering injection technique, storage, missed-dose consequences, and safety monitoring.
Prolia (Denosumab) Geriatric (65+) School and Activity Considerations
A clinician-reviewed guide for adults 65+ on how Prolia (denosumab) affects daily activities, exercise, fall prevention, and community engagement, with dosing facts, safety data, and practical scheduling advice.
Prolia (Denosumab) Geriatric (65+): Off-Label Use, Evidence, and Clinical Guidance
A clinician-reviewed guide to off-label denosumab use in adults 65 and older, covering bone metastases, glucocorticoid-induced osteoporosis, male osteoporosis, renal osteodystrophy, and more, with trial data, dosing, and safety considerations.
Prolia (Denosumab) in Adolescents Ages 12 to 17: What You Need to Know About Off-Label Use
A clinician-reviewed guide to off-label denosumab (Prolia) use in adolescents aged 12-17, covering indications, dosing, bone density considerations, rebound fracture risk, and evidence from published trials.
Prolia (Denosumab) in Adults 65 and Older: Transition to Adult Care Guide
A clinical guide to managing Prolia (denosumab) therapy in geriatric patients 65+, covering dosing, rebound fracture risk, lab monitoring, and safe care transitions from specialty to primary practice.
Prolia (Denosumab) in Children Under 12: What Happens at the Transition to Adult Care
A clinical guide to managing denosumab therapy when pediatric patients under 12 transition to adult endocrinology or rheumatology care, including rebound fracture risk, monitoring protocols, and dosing considerations.
Prolia (Denosumab) Pediatric (<12): Developmental Impact
A comprehensive clinical review of denosumab (Prolia) use in children under 12, covering bone development, growth plate safety, rebound hypercalcemia, dosing evidence, and current FDA status.
Prolia (Denosumab) Pediatric Administration: Caregiver Guide for Children Under 12
A clinician-reviewed guide for caregivers administering Prolia (denosumab) to children under 12, covering injection technique, dosing schedules, storage, side effect monitoring, and when to call the care team.
Prolia (Denosumab) Pediatric School and Activity Considerations for Children Under 12
What parents and care teams need to know about school attendance, physical activity restrictions, fracture risk, and daily life for children under 12 receiving denosumab (Prolia) therapy.
Prolia (Denosumab) Pediatric Use Under Age 12: Off-Label Evidence, Risks, and Clinical Guidance
A clinical deep-dive into off-label denosumab (Prolia) use in children under 12, covering indications, dosing evidence, rebound hypercalcemia risk, and current guideline positions.